Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pleomorphic liposarcoma (PLS) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

pleomorphic liposarcoma

MONDO:0020562

Also known as:PLSpleomorphic liposarcoma (morphologic abnormality)PLLS

Find Clinical TrialsTrials

Overview

Pleomorphic liposarcoma (PLS), the rarest subtype of liposarcoma (LS), is an aggressive, fast growing tumor located usually in the deep soft tissues of the lower and upper extremities. It is characterized by a variable number of pleomorphic lipoblasts and, in contrast to dedifferentiated liposarcoma, it lacks any association with well-differentiated liposarcoma.

Clinical Trials7 registered · 6 recruiting

Clinical Presentation

Features include always present findings: Liposarcoma; and very common findings: Subcutaneous nodule.

Organ System	Phenotype Count	Example Features
Skin	1	Subcutaneous nodule

Explore clinical features

Diagnosis

Biomarker and diagnostic research for pleomorphic liposarcoma has been reported in the published literature.

Prognosis

Phenotype severity distribution: 1 always present feature, 1 very common feature.

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

7 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, procedural interventions, and other interventions. Pipeline includes 3 PHASE2, 3 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06526897](https://clinicaltrials.gov/study/NCT06526897)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:42 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:99969

GARD

Genetic and Rare Diseases Info Center

GARD:19719

Questions for Your Care Team

→Are any of the 7 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	42	26%
Research summaries	36	23%
Laboratory research	33	21%
Testing and diagnosis research	17	11%
Clinical study results	13	8%
Disease patterns and progression	11	7%
Other research	4	3%
New treatment approaches	4	3%

pleomorphic liposarcoma

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications